Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Maze Therapeutics, Inc. (MAZE)
:MAZE
MAZE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.80 - $17.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)224.03K
Market Cap
$532.77M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-3.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,776,978
10 Day Avg. Volume262,881
30 Day Avg. Volume224,029
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Options Prices
Currently, No data available
---
Ownership Overview
16.95%
Insiders
―
Mutual Funds
― Other Institutional Investors
83.05% Public Companies and
Individual Investors
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $10.80 and its highest was $17.00 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $532.77M.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 43,776,978 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
---
Maze Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease. We initiated a Phase 2 trial of our lead drug candidate, MZE829, in November 2024.
---
Technical Analysis
---